Safety and Efficacy of Inhaled Treprostinil in Patients With PAH (INTREPID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01557647
Recruitment Status : Withdrawn
First Posted : March 19, 2012
Last Update Posted : March 26, 2012
Information provided by (Responsible Party):
United Therapeutics

March 14, 2012
March 19, 2012
March 26, 2012
June 2012
December 2015   (Final data collection date for primary outcome measure)
Six-minute walk test [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT01557647 on Archive Site
Time to clinical worsening [ Time Frame: 1 day to 2.5 years. ]
Same as current
Not Provided
Not Provided
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil.
To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pulmonary Arterial Hypertension
  • Drug: Inhaled treprostinil
    0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
  • Drug: Placebo
    placebo inhalation solution
  • Experimental: inhaled treprostinil
    Intervention: Drug: Inhaled treprostinil
  • Placebo Comparator: placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2016
December 2015   (Final data collection date for primary outcome measure)

Eligible subjects must:

  • Be between 18 and 75 years of age at Screening (as defined by date of informed consent is signed),
  • Have a diagnosis of idiopathic or heritable PAH, PAH associated with connective tissue disease (CTD), PAH associated with repaired congenital systemic-to-pulmonary shunts (at least 1 year since repair) or human immunodeficiency virus (HIV) infection, or PAH associated with appetite suppressant or toxin use.
  • Be treatment naïve, or receiving background PAH therapies (e.g., phosphodiesterase type-5 inhibitor (PDE-5i)and / or endothelin receptor antagonist (ERA)) for less than 1 year prior to Screening.
  • Have a 6MWD at Baseline (as measured by the mean value of two 6MWT separated by at least 24 hours, but no more than 14 days) that is between 150 - 500 meters, inclusive.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
United Therapeutics
United Therapeutics
Not Provided
Not Provided
United Therapeutics
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP